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A b s t r a c t
To determine whether genetic factors influence frontal lobe degeneration in Alzheimer’s disease (AD), the laminar 
distributions of diffuse, primitive, and classic β-amyloid (Aβ) peptide deposits were compared in early-onset familial 
AD (EO-FAD) linked to mutations of the amyloid precursor protein (APP) or presenilin 1 (PSEN1) gene, late-onset 
familial AD (LO-FAD), and sporadic AD (SAD). The influence of apolipoprotein E (Apo E) genotype on laminar distri-
bution was also studied. In the majority of FAD and SAD cases, maximum density of the diffuse and primitive Aβ 
deposits occurred in the upper cortical layers, whereas the distribution of the classic Aβ deposits was more variable, 
either occurring in the lower layers, or a double-peaked (bimodal) distribution was present, density peaks occurring 
in upper and lower layers. The cortical layer at which maximum density of Aβ deposits occurred and maximum 
density were similar in EO-FAD, LO-FAD and SAD. In addition, there were no significant differences in distributions 
in cases expressing Apo E ε4 alleles compared with cases expressing the ε2 or ε3 alleles. These results suggest that 
gene expression had relatively little effect on the laminar distribution of Aβ deposits in the frontal lobe of the AD 
cases studied. Hence, the pattern of frontal lobe degeneration in AD is similar regardless of whether it is associated 
with APP and PSEN1, mutation, allelic variation in Apo E, or with SAD.
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Introduction
The neuropathology of Alzheimer’s disease (AD) 
is characterised by the formation of extracellular 
senile plaques (SP) and intracellular neurofibrillary 
tangles (NFT) [5,34]. The most important molecu-
lar constituent of the SP is β-amyloid (Aβ) [28], an 
approximately 4 kDa peptide arising by constitutive 
cleavage of a  trans-membrane amyloid precursor 
protein (APP). A variety of Aβ peptides are formed as 
a result of secretase cleavage of APP [40]. The most 
common of these peptides is Aβ42, found largely in 
discrete Aβ deposits, whereas the more soluble Aβ40 
is also found in association with blood vessels [37] 
and may develop later in the disease [21]. The discov-
ery of Aβ led to the formulation of the ‘amyloid cas-
cade hypothesis’ (ACH), one of the most important 
models of the molecular pathology of AD developed 
over the last 25 years [28]. Essentially, the ACH pro-
poses that the deposition of Aβ is the initial patholo-
gical event in AD leading to the formation of NFT, cell 
death, and cortical degeneration [28]. 
At least four genetic loci are associated with AD: 
the APP gene on chromosome 21 [17,26], the prese-
Communicating author:
Dr Richard A. Armstrong, Vision Sciences, Aston University, Birmingham B4 7ET, UK, phone: 0121-204-4102, fax: 0121-204-4048,
e-mail: R.A.Armstrong@aston.ac.uk
16 Folia Neuropathologica 2015; 53/1
Richard A. Armstrong
nilin PSEN genes on chromosome 14 (PSEN1) [47] 
and chromosome 1 (PSEN2) [32], and the apolipopro-
tein E (Apo E) gene on chromosome 19 [44]. APP and 
PSEN mutation may alter APP metabolism, resulting 
in increased deposition of Aβ peptide, while allelic 
polymorphism of Apo E, and especially the expres-
sion of allele ε4, may influence the proportion of the 
more fibrillogenic Aβ42 formed in the tissue [32,47]. 
These genetic factors, however, may not explain the 
majority of AD cases [27]. Hence, early-onset cases 
linked to APP and PSEN mutations may account for 
less than 5% of total AD [29]. Additional suscepti-
bility genes and environmental factors are there-
fore likely to be involved, especially in sporadic AD 
(SAD) [38,39,41]. In isolated Amish communities, for 
example, 24 markers have been linked to dementia 
[33] and several other linkage studies have shown 
the presence of AD susceptibility genes on chromo-
somes 9, 10, and 12 [48]. Hence, a small number of 
AD cases have been linked recently to the chromo-
some 9 open reading frame 72 (C9ORF72) gene [55].
Three morphological subtypes of Aβ deposit are 
commonly observed in AD: 1) diffuse (‘pre-amyloid’) 
deposits, in which the Aβ is not in a  fibrillar form 
with a β-pleated conformation, dystrophic neurites 
(DN) and paired helical filaments (PHF) being large-
ly absent, 2) primitive (‘neuritic’) deposits, in which 
the Aβ is in a fibrillar form and is associated with 
DN and PHF, and 3) classic (‘dense-cored’) depos-
its, in which Aβ is highly aggregated to form a cen-
tral amyloid plaque ‘core’ surrounded by a ‘ring’ of 
DN [3,8,10-12,20]. In the cerebral cortex in AD, Aβ 
deposits [2] and NFT [54] often exhibit significant 
variation in density across the cortex from pia mater 
to white matter, maximum density occurring within 
different layers [2,54]. The laminar distribution of Aβ 
deposits may be a consequence of degeneration of 
neural pathways that have their neurons of origin 
or axon terminals located within particular layers 
[22]. The main objective of this study was to deter-
mine whether genetic factors influence the laminar 
distribution of Aβ deposits and therefore result in 
a specific type of cortical degeneration in the frontal 
cortex in AD. Hence, laminar distributions of diffuse, 
primitive, and classic Aβ deposits were studied in 
three groups of cases: 1) early-onset familial Alzhei-
mer’s disease (EO-FAD) linked to mutations of either 
amyloid precursor protein (APP717) or presenilin 1 
(PSEN1: G209V, E280A) genes, 2) late-onset familial 
AD (LO-FAD), and 3) sporadic AD (SAD). In addition, 
the influence of Apo E genotype on the distribution 
of Aβ deposits was studied.
Material and methods
Cases
Alzheimer’s disease cases (N = 20; details in 
Table I) were obtained from the Brain Bank, Depart-
ment of Neuropathology, Institute of Psychiatry, 
King’s College, London, UK. Informed consent was 
given for the removal of all brain tissue according to 
the 1996 Declaration of Helsinki (as modified Edin-
burgh, 2000). Patients were clinically assessed and 
all fulfilled the ‘National Institute of Neurological 
and Communicative Disorders and Stroke and the 
Alzheimer Disease and Related Disorders Associa-
tion’ (NINCDS/ADRDA) criteria for probable AD [52]. 
The histological diagnosis of AD was established by 
the presence of widespread neocortical SP consis-
tent with the ‘Consortium to Establish a Registry of 
Alzheimer Disease’ (CERAD) criteria [34] and ‘Nation-
al Institute on Aging (NIA)-Reagan Institute’ criteria 
[30,34]. The cases were divided into three groups: 
1) EO-FAD (onset ≤ 65 years) (n = 4), 2) LO-FAD (≥ 65 
years) (n = 6), and 3) SAD (n = 10) with no evidence 
of familial involvement. 
Tissue preparation
A  block of the frontal cortex was taken at the 
level of the genu of the corpus callosum to study 
the superior frontal gyrus (SFG). Tissue was fixed in 
10% phosphate-buffered formal saline and embed-
ded in paraffin wax. Both immunostaining and thio-
flavin S have been used to stain SP in AD [14,45]. 
Thioflavin S staining indicates that amyloid in these 
plaques contains fibrillar material with a β-pleated 
sheet conformation [14]. By contrast, immunohis-
tochemistry generally reveals more plaques includ-
ing diffuse Aβ deposits which are mainly thioflavin 
S-negative [14]. Hence, to label all types of plaque 
7  µm coronal sections were immunolabelled with 
a rabbit polyclonal antibody (Gift of Prof. B.H. Ander-
ton, Institute of Psychiatry, King’s College London) 
raised to the 12-28 amino acid sequence of the 
Aβ protein and first used to identify Aβ deposit 
subtypes in Down’s syndrome (DS) [50] but which 
also effectively distinguishes the major types of Aβ 
deposit in AD [4,6,7,10,50]. The antibody was used 
at a dilution of 1 in 1200 and the sections incubat-
ed at 4°C overnight. Sections were pretreated with 
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98% formic acid for 6 minutes, which enhances 
Aβ immunoreactivity. Aβ was visualised using the 
streptavidin-biotin horseradish peroxidase proce-
dure with diaminobenzidine as the chromogen. 
Sections were also stained with haematoxylin. Aβ 
deposits were identified in the sections using criteria 
published by Delaere et al. [20]: 1) diffuse deposits 
were 10-200 µm in diameter, lightly stained, irregular 
in shape, and with diffuse boundaries, 2) primitive 
deposits were 20-60 mm, well demarcated, symmet-
rical in shape, and strongly stained, and (3) classic 
deposits were 20-100 mm and had a distinct central 
amyloid core surrounded by a ‘corona’ of DN [20]. 
Morphometric methods
The distribution of the Aβ deposits in the SFG of 
each case was studied from the pia mater to white 
matter using methods described previously [23]. 
Five traverses from the pia mater to the edge of the 
white matter were located at random within each 
gyrus [9]. All deposits were then counted in 200 x 
1000 µm sample fields arranged contiguously, the 
larger dimension of the field parallel with the sur-
face of the pia mater. An eye-piece micrometer was 
used as the sample field and was moved down each 
traverse one step at a  time from the pia mater to 
the edge of the white matter. Histological features of 
the section were used to correctly position the field. 
The mean of the counts from the five traverses was 
calculated to study variations in density of histolo-
gical features across each cortical gyrus.
Data analysis
No attempt was made to locate precisely the 
boundaries between individual cortical layers. First, 
the degree of cortical degeneration present in many 
Table I. Demographic and genetic data of the Alzheimer’s disease (AD) cases studied
Case Sex Age Onset of disease Group Genetics Apo E
1 M 65 – EO-FAD APP717 3/3
2 F 59 – EO-FAD APP717 3/3
3 F 61 – EO-FAD PSEN1 3/3
4 F 45 40 EO-FAD PSEN1 2/3
5 F 72 66 LO-FAD ND 2/3
6 F 86 80 LO-FAD ND 3/4
7 F 77 72 LO-FAD ND 3/3
8 F 79 68 LO-FAD ND 3/4
9 F 85 76 LO-FAD ND 3/3
10 F 89 – LO-FAD ND 3/3
11 M 80 77 SAD – 3/3
12 F 87 82 SAD – 3/4
13 F 64 59 SAD – 4/4
14 F 91 83 SAD – 3/4
15 M 73 66 SAD – 2/3
16 F 82 75 SAD – ND
17 F 91 85 SAD – 3/4
18 F 86 83 SAD – 3/4
19 F 90 – SAD – ND
20 M 82 78 SAD – 3/3
Apo E – apolipoprotein E, APP – amyloid precursor protein, EO-FAD – early-onset familial Alzheimer’s disease, LO-FAD – late-onset familial Alzheimer’s disease, 
SAD – sporadic Alzheimer’s disease, PSEN1 – presenilin 1, M – male, F – female, ND – not determined
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gyri made laminar identification difficult. Second, 
identification was especially difficult in the frontal cor-
tex because it exhibits a heterotypical structure, i.e., 
six layers cannot always be clearly identified and vary 
in prominence from case to case. Third, Aβ deposits 
appeared to exhibit complex patterns of distribution 
across the cortex rather than being confined to spe-
cific layers. Hence, variations in density of Aβ deposits 
with distance across the cortex were analysed using 
a polynomial curve-fitting procedure (STATISTICA soft-
ware, StatSoft Inc., 2300 East 14th St, Tulsa, OK, 74104, 
USA) [2,49]. For each gyrus, polynomials of order 1, 
2, 3 up to the 4th order were fitted successively to 
the data. Hence, second-order curves are parabolic, 
third-order curves are ‘S’ shaped, and fourth-order 
curves are double-peaked (bimodal). With each fitted 
polynomial, the correlation coefficients (Pearson’s ‘r’), 
regression coefficients, standard errors of the mean 
(SEM), values of t, and the residual mean square were 
obtained. At each stage, the reduction in the sums of 
squares (SS) was tested for significance. A polynomi-
al was accepted as the best fit using the procedure 
described by Snedecor and Cochran [49], viz. when 
either a  non-significant value of F was obtained or 
there was little gain in explained variance. The dis-
tributions of the Aβ deposits across the cortex were 
classified initially into three groups: 1) a single den-
sity peak was present (unimodal distribution), peak 
density being located in either upper or lower layers, 
2) two density peaks were present (bimodal distri-
bution), density peaks occurring in upper and low-
er layers, and 3) there was no significant change in 
density across the cortex, Aβ deposits not being 
confined to particular layers. Bimodal distributions 
were then classified further according to whether 
the density peaks in the upper and lower layers were 
of similar or different magnitude. To study the effect 
of Apo E genotype, cases were classified into two 
groups: those not expressing allele ε4, i.e., genotypes 
ε2/3 and ε3/3, and those expressing at least one allele 
ε4, i.e., genotypes ε3/4 and ε4/4. In addition, the loca-
tion of peak density and the maximum density of 
deposits were compared in EO-FAD, LO-FAD, and SAD. 
Hence, the point of maximum density (peak density) 
was identified for each deposit type for each gyrus 
while location of the peak was determined as the 
distance from the pia mater to that of the maximum 
density of Aβ deposits, expressed as a percentage of 
the total distance from the pia mater to the edge of 
the white matter. 
Results
Examples of the distribution of Aβ peptide depo-
sits across the SFG are shown in Figures 1 and 2. In 
a case of EO-FAD (Fig. 1) (PSEN1 mutation), Aβ depo-
sits occurred across the cortex with a greater density 
of larger deposits in the upper layers. By contrast, in 
a case of SAD (Fig. 2), Aβ deposits occur largely in the 
lower layers. 
Examples of the laminar distribution of the dif-
fuse, primitive, and classic Aβ deposits in the SFG 
of a  single EO-FAD case (case 2, APP mutation) is 
shown in Figure 3. The distribution of the diffuse 
deposits was fitted by a  first-order (linear) regres-
sion (r = 0.82, p < 0.01) consistent with greater 
densities of diffuse deposits in the upper layers and 
a  linear decrease in density across the cortex from 
pia mater to white matter. The distribution of the 
primitive Aβ deposits was fitted by a  third-order 
polynomial (r = 0.91, p < 0.001) with a large density 
peak in the upper layers, while the classic deposits 
were also fitted by a third-order polynomial (r = 0.82, 
p < 0.01) with slightly higher densities adjacent to 
the pia mater and in the lower layers.
A  comparison of the laminar distributions is 
shown in Table II. In FAD, diffuse Aβ deposits exhib-
Fig. 1. Distribution of β-amyloid (Aβ) peptide 
deposits (arrowhead) in the superior frontal 
gyrus (SFG) in a case of early-onset familial Alz-
heimer’s disease (EO-FAD) (PSEN1 mutation). 
Aβ deposits occur across the cortex in all layers 
but with a greater density of larger-sized depos-
its in the upper layers. Aβ immunohistochemis-
try, haematoxylin, bar = 0.75 mm.
19Folia Neuropathologica 2015; 53/1
Laminar distribution of β-amyloid (Aβ) peptide deposits in the frontal lobe in familial and sporadic Alzheimer’s disease
ited a density peak in the upper layers in 6/10 cas-
es, and the primitive deposits did so in 9/10 cases. 
The distribution of the classic deposits was more 
variable; in 6/10 cases there was either a  density 
peak in lower cortex or a bimodal distribution was 
present with density peaks in upper and lower layers. 
In SAD, diffuse and primitive Aβ deposits exhibited 
a density peak in the upper cortex in 7/10 cases and 
9/10 cases respectively. Distribution of the classic Aβ 
deposits was more variable, a  density peak in the 
lower layers or a bimodal distribution being present 
in 5/10 cases. The frequency of the various types 
of distribution of the diffuse (c2 = 3.74, p > 0.05), 
primitive (c2 = 0.71, p > 0.05), and classic (c2 = 11.18, 
p > 0.05) Aβ deposits was similar in EO-FAD, LO-SAD, 
and SAD.
Comparison of the mean location of maximum 
density and peak density of deposits among the 
three groups of cases is shown in Table III. Although 
there were significant differences in the layers at 
which peak density occurred among Aβ deposit sub-
types (F = 4.44, p < 0.01), there were no significant 
differences among EO-FAD, LO-FAD, or SAD (F = 0.89, 
p > 0.05). In addition, there were no significant dif-
ferences in peak density of Aβ deposits (F = 3.28, 
p > 0.05) among patient groups. 
A  comparison of the distributions exhibited by 
the Aβ deposits in cases classified according to Apo E 
genotype groups is shown in Table IV. There were 
no significant differences in distribution of diffuse 
(c2 = 2.55, p < 0.05), primitive (c2 = 0.003, p < 0.05), 
or classic (c2 = 3.41, p < 0.05) Aβ deposits in cases 
expressing Apo E genotypes ε2/3 and ε3/3, compared 
with those expressing genotypes ε3/4 and ε4/4.
Discussion
The objective of this study was to determine 
whether genetic factors were associated with a spe-
cific pattern of cortical degeneration, as revealed 
by the deposition of Aβ deposits in the frontal cor-
tex in AD. The data confirm the need for quantita-
tive assessment of Aβ deposition in different layers 
of cortex as deposits often occur over many layers 
with variation in abundance across the cortex. This 
study demonstrated: 1) laminar distributions of 
diffuse, primitive, and classic Aβ deposit subtypes 
were essentially similar in EO-FAD, LO-FAD, and SAD, 
2) within FAD, laminar distributions were similar in 
APP/PSEN1 cases compared with LO-FAD, and 3) lam-
inar distributions were similar in cases expressing 
Apo E ε4 alleles compared with cases expressing ε2 
or ε3 alleles.
The data suggest no significant differences in Aβ 
deposit density in EO-FAD, LO-FAD, and SAD or when 
cases were classified according to Apo E genotype. 
Previous quantitative studies comparing SP or Aβ 
Fig. 2. Distribution of β-amyloid (Aβ deposits) 
(arrowhead) across the superior frontal gyrus 
(SFG) in a case of sporadic Alzheimer’s disease 
(SAD). Aβ deposits occur largely in the lower lay-
ers. Aβ immunohistochemistry, haematoxylin, 
bar = 0.75 mm.
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Fig. 3. Examples of the laminar distribution of 
the diffuse, primitive, and classic β-amyloid (Aβ 
deposits) in frontal lobe of a case of early-onset 
familial Alzheimer’s disease (EO-FAD) (case 2, 
amyloid precursor protein (APP) gene mutation).
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deposit abundance in FAD and SAD have been con-
troversial [16,18,24,36]. Hence, no significant differ-
ences in severity scores of SP were observed in FAD 
and SAD [36], and Aβ ‘load’ in the frontal cortex and 
temporal isocortex was similar in SAD and FAD cas-
es linked to the APP717 mutation [16]. Nevertheless, 
cultured cells expressing a double mutation in APP 
produced six times more Aβ than normal cells [18]. 
In addition, other studies have reported increased 
amyloid deposition in individuals expressing allele ε4 
[24]. However, it is possible that Aβ deposition could 
be more widely distributed across the cortical layers 
of the SFG in FAD, but with similar peak densities. 
In the SFG of both SAD and FAD, maximum densi-
ty of the diffuse and primitive Aβ deposits occurred 
most frequently in the upper layers. By contrast, the 
distribution of the classic deposits was more vari-
able, peak densities occurring either in the lower lay-
Table II. Comparison of the frequencies of different types of laminar distribution of β-amyloid (Aβ) deposits 
in superior frontal gyrus (SFG) in three groups of cases: early-onset familial Alzheimer’s disease (EO-FAD), 
late-onset familial AD (LO-FAD), and sporadic AD (SAD). Data are the number of cases in which a particular 
type of laminar distribution is present
Group Deposit type Type of laminar distribution
UL LL B NS
EO-FAD Diffuse 3 0 1 0
Primitive 4 0 0 0
Classic 2 0 2 0
LO-FAD Diffuse 3 1 1 1
Primitive 5 0 0 1
Classic 0 4 0 2
SAD Diffuse 7 1 0 2
Primitive 9 0 0 1
Classic 2 4 1 3
Comparison of frequencies between groups: c2 contingency tables: diffuse deposits c2 = 5.09 (6 DF, p > 0.05), primitive deposits c2 = 0.74 (2 DF, p > 0.05), classic 
deposits c2 = 11.26 (6 DF, p > 0.05)
UL – maximum Aβ deposit density occurred in upper cortical layers, LL – maximum Aβ deposit density occurred in lower cortical layers, B – bimodal distribution 
with peaks of density in upper and lower layers, NS – no significant change in density of Aβ deposits across the cortex
Table III. Comparison of mean peak location, i.e., percentage distance from the pia mater at which max-
imum density of β-amyloid (Aβ) deposits occurred expressed as a percentage of the width of the gray 
matter, and mean peak density, i.e., the actual density of deposits at the peak (mm2) in the superior frontal 
gyrus (SFG) in three groups of cases: early-onset familial Alzheimer’s disease (EO-FAD), late-onset familial 
AD (LO-FAD), and sporadic AD (SAD). Standard errors of the mean (SEM) are in parentheses 
Group Aβ deposit subtype
Diffuse Primitive Classic
EO-FAD Peak location 32.5 (12.11) 21.3 (5.98) 40.0 (12.54)
Peak density 36.5 (6.39) 86.5 (21.85) 12.3 (2.19)
LO-FAD Peak location 39.5 (9.89) 31.7 (4.88) 51.7 (10.24)
Peak density 28.0 (5.22) 70.3 (17.84) 8.17 (1.79)
SAD Peak location 32.0 (9.66) 27.20 (3.69) 55.10 (6.09)
Peak density 20.8 (3.20) 38.3 (10.76) 10.3 (1.50)
Analysis of variance (ANOVA): 1) Peak location: patient group F = 0.89 (p > 0.05), deposit type F = 4.44 (p < 0.01), interaction F = 0.22 (p > 0.05); 2) Peak density: 
patient group F = 3.28 (p > 0.05), deposit type F = 18.73 (p < 0.001), interaction F = 1.36 (p > 0.05)
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ers, or in both upper and lower layers. Similar results 
have been reported in studies of the laminar distri-
bution of SP [15,19], Apo E-immunoreactive SP [53], 
neuritic plaques (NP) [42], and Aβ deposits in AD [2], 
which are frequently abundant in layers II and III. In 
addition, in a  transgenic mouse model expressing 
the APP717 mutation, Aβ deposits were most abun-
dant in layers II and III, similar to AD [51]. However, 
aged dogs often show a different distribution of Aβ 
deposits to humans, being usually abundant in the 
deep cortical layers but with evidence of spread to 
superficial cortical layers with increasing age [43].
Various hypotheses could explain the laminar 
distribution of Aβ deposits in the SFG in AD. First, 
mRNA of APP is preferentially expressed by the large 
pyramidal neurons in layers III and V [13]. Degenera-
tion of these neurons could then result in increased 
secretion of APP and formation of Aβ deposits within 
these layers [4]. Second, interleukin-immunoreactive 
microglia (IL-Mg) have a similar laminar distribution 
as APP-immunoreactive NP [46]. Hence, the laminar 
distribution of microglia could be a factor determin-
ing the distribution of the Aβ deposits. Third, the 
laminar distribution of the classic deposits could be 
spatially related to blood vessels [2,37]. Large blood 
vessels often exhibit a  bimodal distribution in the 
cortex, whereas smaller capillaries occur at max-
imum density in the deeper layers [2]. In addition, 
Akiyama et al. [1] found that Aβ deposits accumu-
lated vertically in columns, with blood vessels often 
occurring perpendicular to the column and pene-
trating its centre. Previous studies suggest, howev-
er, that although classic Aβ deposits are clustered 
around blood vessels in SAD [6], there are fewer spa-
tial associations with blood vessels in FAD [7].
Laminar distributions of Aβ deposits in frontal 
lobe AD are essentially similar in the FAD and SAD 
cases examined and similar whether Apo E allele 
ε4 was present or not [31]. In addition, among FAD 
cases, there was no evidence that a specific type of 
laminar distribution was influenced by genetic sub-
type. Hence, neither APP/PSEN1 mutations nor the 
presence of Apo E allele ε4 uniquely determines Aβ 
deposition and therefore the pattern of frontal lobe 
degeneration in AD. Uchihara et al. [53] found that 
Apo E labelled a subset of deposits in lamina III with 
more Apo E-immunoreactive diffuse deposits in the 
deeper layers. However, only a  proportion of the 
diffuse deposits were Apo E-immunoreactive, sug-
gesting that Apo E was not involved in the process 
of cortical degeneration but immunoreactivity was 
acquired by certain deposits later in the disease. 
Hence, pathological changes initiated by the various 
genetic changes in FAD and, by other causes in SAD, 
appear to follow a parallel course resulting in very 
similar patterns of cortical degeneration in the SFG.
In conclusion, there were no essential differences 
in the laminar distribution of the Aβ deposits in the 
SFG between FAD and SAD, or between different sub-
types of FAD. Hence, APP and PSEN1 mutations and 
the presence of Apo E genotype ε4 appear to have 
little influence on laminar distribution. Although the 
Table IV. Comparison of frequencies of different types of laminar distribution of Aβ deposits in superior 
frontal gyrus (SFG) of Alzheimer’s disease (AD) cases divided into two groups according to apolipoprotein 
(Apo E) genotype, i.e., those expressing genotypes ε2/3 and ε3/3 compared with those expressing gen-
otypes ε3/4 and ε4/4. Data are the number of cases in which a particular type of laminar distribution is 
present
Group Aβ deposit  
subtype
Laminar distribution
UL LL B NS
ε2/3, ε3/3 Diffuse 8 0 2 1
Primitive 10 0 0 1
Classic 3 4 2 2
ε3/4, ε4/4 Diffuse 7 0 0 0
Primitive 7 0 0 0
Classic 1 5 0 1
Chi-square (c2) contingency tables: diffuse deposits c2 = 2.29 (2 DF, p > 0.05), primitive deposits c2 = 0.006 (1 DF, p > 0.05), classic deposits c2 = 2.69 (3 DF, p > 0.05)
UL – maximum Aβ deposit density occurred in upper cortical layers, LL – maximum Aβ deposit density occurred in lower cortical layers, B – bimodal distribution 
with peaks of density in upper and lower layers, NS – no significant change in density of Aβ deposits across the cortex
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mechanism of generating fibrillogenic species of Aβ 
may differ among disease subtypes, gene expres-
sion appears to have little effect on the pattern of 
degeneration of the frontal lobe in AD.
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